TG THERAPEUTICS, INC.

TG THERAPEUTICS, INC. (TGTX) is a US-listed equity tracked across major market indices. TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.

The company reports trailing twelve-month revenue of $2.79M and net income of $19.78M. Key metrics include a return on equity of 3.4%, a debt-to-equity ratio of 1.62.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for TGTX to support both active traders and long-term investors.